The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis

Helmut Butzkuevena Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia;b The Alfred Hospital, Melbourne, VIC, Australia

Jan Hillertc Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

Merja Soilu-Hänninend Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland

Tjalf Ziemssene Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany

Jens Kuhlef Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland;g Department of Neurology, University Hospital and University of Basel, Basel, Switzerland

Stig Wergelandh Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway;i Department of Clinical Medicine, University of Bergen, Bergen, Norway

Melinda Magyarij Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

Joseph R. Bergerk Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Nicholas Moorel Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France

Aida Aydemirm EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA

Irene Bezemern Global Epidemiology, IQVIA, Amsterdam, The Netherlands

Meritxell Sabidóo Merck Healthcare KGaA, Darmstadt, GermanyCorrespondence[email protected]

show all

The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis

2. MAV_CLARION Interim Resuls Manuscript_Supplement.docx

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis

2. MAV_CLARION Interim Resuls Manuscript_Supplement.docx

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date